CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen®, aimed at treating late-stage pancreatic cancer, with an expected gross proceeds of $12 million if fully subscribed [2][5]. Group 1: Rights Offering Details - The rights offering allows holders of the company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [3][4]. - Each unit consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock, with the preferred stock convertible into 833 shares of common stock at a conversion price of $1.20 per share [4]. - The subscription rights are non-transferable and must be exercised by 5:00 p.m. Eastern Time on February 27, 2026, unless extended by the company [6]. Group 2: Financial Implications - If the rights offering is fully subscribed, the company anticipates receiving aggregate gross proceeds of $12 million [5]. - Holders who fully exercise their basic subscription rights will have the opportunity to subscribe for additional units that remain unsubscribed due to unexercised basic subscription rights [5]. Group 3: Company Background - AIM ImmunoTech Inc. is focused on the research and development of Ampligen® (rintatolimod), which is a highly selective TLR3 agonist immuno-modulator showing promise in treating late-stage pancreatic cancer [12].